For the quarter ending 2026-03-31, AMST had -$524,658 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of capitalized software | - | - | - | 90,869 |
| Net revenue | - | - | - | 110,459 |
| Interest income | - | - | - | 77,396 |
| Impairment of capitalized software | - | - | - | 90,869 |
| Stock-based compensation expense | - | - | - | 226,053 |
| Advertising and marketing expenses | - | - | - | 174,227 |
| Depreciation and amortization, net of deferred costs | - | - | - | 55,503 |
| Professional fees | - | - | - | 591,918 |
| Personnel-related expenses | - | - | - | 1,823,715 |
| Director restricted stock unit expense | - | - | - | 300 |
| Warrants issued for underwriting fee | - | - | - | 95,984 |
| Technology and development expense | - | - | - | 69,478 |
| Other segment items | - | - | - | 377,193 |
| Segment net loss | - | - | - | -3,617,086 |
| Net loss | -678,061 | -732,548 | -642,266 | -3,617,086 |
| Depreciation and amortization | 71,373 | 67,740 | 60,440 | 433,803 |
| Stock-based compensation expense | 72,252 | 72,252 | 72,252 | 226,053 |
| Warrants issued for underwriting fee | - | - | - | 95,984 |
| Forfeiture of accrued director compensation | - | - | - | -200,000 |
| Allowance for doubtful accounts | 7,964 | - | - | - |
| Accounts receivable | 19,742 | -3,147 | 4,003 | -23,719 |
| Prepaid expenses and other current assets | 3,136 | 93,828 | -28,771 | -309,389 |
| Accounts payable | -6,583 | 5,530 | -6,051 | -23,494 |
| Accrued compensation | 118,925 | 71,717 | 133,858 | 209,813 |
| Deferred revenue | -12,150 | -8,530 | -12,090 | 36,745 |
| Other accrued liabilities | 0 | -6,564 | -46,676 | -41,043 |
| Net cash and cash equivalents used in operating activities | -449,158 | -621,084 | -415,765 | -2,455,248 |
| Investment in capitalized software | 75,500 | 43,600 | 87,600 | 378,300 |
| Net cash and cash equivalents used in investing activities | -75,500 | -43,600 | -87,600 | -378,300 |
| Proceeds from the sale of common stock | - | - | - | 3,095,950 |
| Net cash and cash equivalents provided by financing activity | - | - | - | 3,095,950 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -524,658 | -664,684 | -503,365 | 262,402 |
| Cash and cash equivalents at beginning of period | - | 1,930,053 | 2,433,418 | 2,171,016 |
| Cash and cash equivalents at end of period | - | 1,265,369 | 1,930,053 | 2,433,418 |
Amesite Inc. (AMST)
Amesite Inc. (AMST)